Related Experiment Videos
[Beta-cell secretion in patients with thalassemia major]
F Massolo1, S Forese, A Gallinelli
1Istituto di Clinica Pediatrica, Università degli Studi di Modena.
Insights
Diabetes mellitus frequently complicates thalassemia major. This study found altered insulin secretion in thalassemic patients, even with residual beta-cell function in some diabetic individuals.
Area of Science:
- Endocrinology
- Hematology
- Metabolic Disorders
Context:
- Thalassemia major patients often develop diabetes mellitus.
- Transfusion and chelation therapies are standard care.
- Beta-cell function in these patients requires further investigation.
Purpose:
- To evaluate beta-cell secretion in thalassemia major patients.
- To assess insulin secretion in diabetic and non-diabetic thalassemic individuals.
Summary:
- A study assessed beta-cell secretion in 24 thalassemia major patients.
- Three diabetic patients showed slight residual beta-cell secretion via C-peptide challenge.
- Intravenous glucose tolerance tests revealed variable insulin secretion in non-diabetic patients.
- Insulin secretion was not correlated with ferritin levels, family history of diabetes, or patient age.
Impact:
- Confirms frequent alterations in insulin secretion in thalassemia major.
- Highlights the need for monitoring beta-cell function in these patients.
- Provides insights into the endocrine complications of thalassemia major management.
Abstract:
Diabetes mellitus is one of the main endocrinological disease complicating the course of thalassemia major. This study aimed evaluate beta-cell secretion in 24 patients with thalassemia major attending the hematological Day Hospital at the Pediatric Clinic in Modena where transfusion therapy is performed in all thalassemic patients so as to maintain minimum hemoglobin levels above 10.5 g/dl, together with intensive ferrochelating therapy (desferrioxamine 50-60 mg/kg/die s.c. 6 days a week). A C peptide challenge with glucagon was performed in three patients already receiving insulin therapy for diabetes mellitus; this unexpectedly revealed a slight residual beta-cell secretion. An intravenous glucose tolerance test (IVGTT) was performed in the remaining 21 non-diabetic patients, with widely varying findings regarding insulin secretion: from below 50 microUl/ml in 5 patients to above 200 microUl/ml in 5 patients, and between 50 and 150 microUl/ml in the remaining 11 patients. This study therefore confirmed that insulin secretion frequently alters in thalassemic patients. Moreover, insulin secretion is not correlated to ferritinemia or influenced by familiar diabetes or patient age.